Fig. 1: Timeframe for analysis for PASADENA and PPMI. | Nature Medicine

Fig. 1: Timeframe for analysis for PASADENA and PPMI.

From: Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

Fig. 1

In PASADENA, the delayed-start group received placebo during the first year of the trial (light gray bar), after which they were switched to prasinezumab (light blue bar). The early-start group (dark blue bar) received prasinezumab for the whole duration of the trial. The PPMI study (dark gray bar) received no intervention.

Back to article page